GlaxoSmithKline: EU Grants Variation To Tyverb Conditional Marketing Approval

Dow Jones -- GlaxoSmithKline PLC Wednesday confirmed that the European Commission (EC) has granted a variation to the conditional marketing authorization for Tyverb (lapatinib) in the European Union for a new therapeutic indication.